Steffi Oesterreich

Jul 19, 2024 | nature.com | Steffi Oesterreich |Adrian Lee |Fangyuan Chen |Rachel C. Jankowitz |Rita A. Mukhtar |Matthew J Sikora | +3 more

AbstractThere is growing awareness of the unique etiology, biology, and clinical presentation of invasive lobular breast cancer (ILC), but additional research is needed to ensure translation of findings into management and treatment guidelines. We conducted a survey with input from breast cancer physicians, laboratory-based researchers, and patients to analyze the current understanding of ILC, and identify consensus research questions.

Feb 19, 2024 | pharmafocusasia.com | Jian Zou |Osama Shiraz Shah |Yu-Chiao Chiu |Tianzhou Ma |Jennifer Atkinson |Steffi Oesterreich | +1 more

Jian Zou, Osama Shah, Yu-Chiao Chiu, Tianzhou Ma, Jennifer M. Atkinson, Steffi Oesterreich, Adrian V. Lee, George C. Tseng. AbstractCancer models are instrumental as a substitute for human studies and to expedite basic, translational, and clinical cancer research. For a given cancer type, a wide selection of models, such as cell lines, patient-derived xenografts, organoids and genetically modified murine models, are often available to researchers.

Jul 13, 2023 | nature.com | Jing Yu |Beth Clark |Jeffrey L. Fine |Adrian Lee |Steffi Oesterreich |Thais Basili | +5 more

AbstractThis study describes “lobular-like invasive mammary carcinomas” (LLIMCas), a group of low- to intermediate-grade invasive mammary carcinomas with discohesive, diffusely infiltrative cells showing retained circumferential membranous immunoreactivity for both E-cadherin and p120. We analyzed the clinical-pathologic features of 166 LLIMCas compared to 104 classical invasive lobular carcinomas (ILCs) and 100 grade 1 and 2 invasive ductal carcinomas (IDCs).